Quantum BioPharma Settles Legal Dispute with Former CEO for $2.35 Million

Quantum BioPharma Ltd. has finalized a $2.35 million settlement with former Executive Chairman and CEO Dr. Raza Bokhari, bringing closure to multiple legal disputes stemming from a 2021 proxy contest. The global settlement, signed by Co-Chairmen Zeeshan Saeed and Anthony Durkacz, ensures that all legal proceedings in the United States and Canada are resolved.

Under the terms of the agreement, Bokhari will pay the company $2.35 million, which represents a non-dilutive capital injection. The settlement also includes a mutual agreement to bar future litigation between the parties, with both sides maintaining that their previous actions were in the company's best interest.

This resolution marks a significant milestone for Quantum BioPharma, a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders. The settlement removes potential legal distractions and allows the company to continue its strategic focus on research and development, particularly its lead compound Lucid-MS, which shows promise in preventing and reversing myelin degradation associated with multiple sclerosis.

The company's diverse portfolio, including strategic investments and a partial stake in Celly Nutrition Corp., positions Quantum BioPharma to continue advancing its innovative biotech solutions. By resolving this legal dispute efficiently, the company demonstrates its commitment to strategic growth and shareholder value.